Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Sintilimab + SOX for cStage III Gastric/GEJ Cancer
NCT05594381Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2022
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Pathological Complete Response Rate at 6 months. Status: unknown.
02
Drugs
sintilimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05594381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05594381.